Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Decreases By 25.4%

AlloVir, Inc. (NASDAQ:ALVR) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,260,000 shares, a decrease of 25.4% from the December 15th total of 1,690,000 shares. Based on an average daily trading volume, of 370,200 shares, the short-interest ratio is presently 3.4 days.

AlloVir Trading Down 4.7 %

AlloVir stock opened at $0.38 on Thursday. The firm has a 50-day moving average of $0.52 and a 200-day moving average of $0.69. The firm has a market cap of $44.04 million, a P/E ratio of -0.43 and a beta of 0.65. AlloVir has a 1-year low of $0.38 and a 1-year high of $1.05.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10.

Hedge Funds Weigh In On AlloVir

A hedge fund recently raised its stake in AlloVir stock. Cubist Systematic Strategies LLC increased its position in AlloVir, Inc. (NASDAQ:ALVR) by 152.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 49,816 shares of the company’s stock after purchasing an additional 30,072 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 as of its most recent filing with the Securities & Exchange Commission. 66.05% of the stock is owned by institutional investors.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.